COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
2상
조기 종료
NCT05000216
| 대상 질환 | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Pemphigus Vulgaris, Multiple Sclerosis |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 258 명 |
|---|
| 중재(약물) | Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX) |
|---|
| 시작일 | 2021년 8월 13일 |
|---|
| 완료일 | 2023년 6월 22일 |
|---|
| 결과 공개일 | 2025년 8월 22일 |
|---|
요약
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result \>200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 vaccine. The study will focus on 5 autoimmune diseases in adults: * Systemic Lupus Erythematosus (SLE) * Rheumatoid Arthritis (RA) * Multiple Sclerosis (MS) * Systemic Sclerosis (SSc), and * Pemphigus. This study will focus on 4 autoimmune diseases in pediatric participants: * Systemic Lupus Erythematosus (SLE) * Juvenile Idiopathic Arthritis (JIA) * Pediatric-Onset Multiple Sclerosis (POMS) * Juvenile Dermatomyositis (JDM)
Percent of Stage 1 Adult Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort A, Arm A1: Moderna mRNA-1273 + Continue IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A4: Moderna mRNA-1273 + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A2: Pfizer-BioNTech + Continue IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A5: Pfizer-BioNTech + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort A, Arm A6: Janssen + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort B, Arm B1: Moderna mRNA-1273 + Continue IS (MTX) | NA Percentage of participants |
|---|
Percent of Stage 2 Adult Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort D, Arm D2: Alternative mRNA + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort D, Arm D4: Sanofi-GSK + Withhold IS (MMF or MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2: Alternative mRNA + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort E, Arm E4: Sanofi-GSK + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort F, Arm F2: Alternative mRNA + Withhold IS (BCDT) | NA Percentage of participants |
|---|
| Cohort F, Arm F3: Moderna mRNA-1273 + Withhold IS (BCDT) | NA Percentage of participants |
|---|
Percent of Stage 2 Pediatric Participants Who Have a Protective Antibody Response at Week 4
Week 4 Status Post Receipt of COVID-19 Vaccination · Percentage of participants
| Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX) | NA Percentage of participants |
|---|
| Cohort D, Arm D2P: Moderna mRNA-1273 + Withhold IS (MMF/MPA) | NA Percentage of participants |
|---|
| Cohort E, Arm E2P: Moderna mRNA-1273 + Withhold IS (MTX) | NA Percentage of participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.